The effects of concomitant administration of antimalarial drugs, oral polio vaccine, or yellow fever vaccine on the immune response elicited by the Vibrio cholerae CVD103-HgR and Salmonella typhi Ty21a live oral vaccines were investigated. Healthy adults were immunized with CVD103-HgR alone or combined with Ty21a. Subjects were randomized to simultaneously receive mefloquine, chloroquine or proguanil, or oral polio or yellow fever vaccine. The vibriocidal antibody seroconversion rate was significantly reduced (P Å .008) only in the group that received chloroquine with the CVD103-HgR. The geometric mean vibriocidal antibody titer was significantly decreased in the groups that received chloroquine (P Å .001) or mefloquine (P Å .02) compared with titers in groups that received CVD103-HgR alone. However, similar immunosuppressive effects were not observed in the groups immunized with Ty21a and CVD103-HgR. Only the concomitant administration of proguanil effected a significant (P Å .013) decline in the anti -S. typhi lipopolysaccharide antibody response. These results indicate that chloroquine and proguanil should not be simultaneously administered with the CVD103-HgR and Ty21a vaccine strains, respectively.
Live oral attenuated vaccines against polio, typhoid fever, administration of multiple oral vaccines could increase the frequency and severity of adverse reactions compared with those and cholera are licensed for human use [1 -3] . These vaccines have the distinct advantage of stimulating local intestinal imwhen vaccines are given individually. We have recently demonstrated that the Ty21a and CVD103-munity, thereby blocking infection at the earliest possible stage. In addition, their ease of administration greatly facilitates mass HgR vaccine strains could be simultaneously administered without compromising safety or immunogenicity of either vaccination campaigns. Adverse reactions associated with the use of the Salmonella typhi Ty21a and Vibrio cholerae strain [9, 10] . This finding paves the way for the development of additional multivalent live oral vaccine formulations. CVD103-HgR vaccine strains are infrequent, mild, and transient [4, 5] . These products have served as models for the future
The effects of simultaneous administration of live vaccines or the concomitant use of antimalarial drugs with antibacterial development of vaccines against a wide variety of bacterial and viral enteric pathogens.
activity on the immune response to immunization have not been studied in great detail. Chloroquine has been shown to In order to induce a protective immune response, live vaccines must undergo a limited degree of replication in vivo.
significantly decrease the immune response to parenterally administered human diploid cell -derived rabies vaccine [11] . Interference with this process would be expected to diminish the level of immunity provided. For example, the concomitant When administered together, parenteral cholera and yellow fever vaccines have an immunosuppressive effect on each other use of antibiotics or antimalarial drugs with activity against live bacterial vaccine strains could markedly suppress their [12] . The fact that many travelers are often prescribed §1 of the above-mentioned vaccines together with an antimalarial multiplication, hence lowering the level of protection conferred [5 -8] . Another potential concern is that the coadministration drug makes these issues of significant practical importance. We therefore conducted a study among Austrian travelers to of §2 live oral vaccines could interfere with the immune response to §1 of the vaccine strains. Finally, the simultaneous determine the effect of simultaneously administering various vaccines and antimalarial drugs on the immune response to the Ty21a and CVD103-HgR vaccine strains.
Ty21a. The other chamber contained a buffer composed of 2.5 g Serologic analysis. Antibody titrations were done in a blinded manner. Vibriocidal antibody titers were determined using a microof sodium bicarbonate and 1.65 g of ascorbic acid.
Trivalent oral polio vaccine (Polio Sabine Oral; SmithKline titer plate assay as previously described, using V. cholerae 569B (classical, Inaba) as the test strain [13] . A significant response was Beecham, Riksensart, Belgium) was administered as a single 0.5-mL dose.
defined as a §4-fold rise in titer over baseline. Anti-S. typhi IgG and IgA lipopolysaccharide antibodies were quantitated using an Yellow fever vaccine (Arilvax, lot no. 1/350; Burroughs Wellcome, Beckenham, UK) contained the attenuated 17D strain of ELISA as described elsewhere [14] . An increase of §0.15 optical density units over baseline was considered significant. yellow fever virus. A single 0.5-mL subcutaneous injection was administered in the deltoid area.
Statistical analysis. Statistical differences in vibriocidal and anti-S. typhi IgG response rates between groups were determined Antimalarial drugs. Mefloquine (Lariam F; Hoffmann-LaRoche, Basel, Switzerland) was administered orally in tablet form by x 2 analysis. Differences in the geometric mean antivibriocidal titers between groups were determined using a one-tailed t test. (250 mg) at weekly intervals. Chloroquine (Resochin; Bayer, Leverkusen, Germany) was administered in tablet form (2 tablets cor-
The rate of adverse reactions between groups was analyzed using x 2 analysis with Yates's correction. responding to 250 mg of chloroquine diphosphate) at weekly intervals. Proguanil (Paludrine; Zeneca, Macclesfield, UK) was administered orally (2 100-mg tablets) daily for 7 days. tively high, with such nonspecific events as malaise and headStudy design. Healthy men and women §18 years of age were ache being reported by ú50% of subjects in several groups.
Results

MIC determinations. The in vitro MICs
recruited from the student body of the University of Vienna. Exclusion criteria included acute febrile illness, history of allergies, This can most likely be attributed to the fact that the volunteers immunization against either cholera or typhoid fever within the were highly motivated to report any and all symptoms that past 3 years, immunization against polio within the past 5 years, could be related to vaccination. The vast majority of reactions previous vaccination against yellow fever, use of antibiotics within were transient, mild, and resolved without medical intervention. pooled and compared with the pooled values for the 2 control mL, respectively. Only proguanil was found to exert a significant (P Å .013) decrease upon the combined IgG or IgA serum groups (A and G). Chloroquine was still found to significantly (P Å .014) lower the seroconversion rate and postimmunization anti -S. typhi lipopolysaccharide antibody response. Mefloquine, which had the highest level of in vitro activity against GMT (P Å .001). Similarly, mefloquine treatment resulted in a slightly decreased vibriocidal GMT (P Å .032), although the Ty21a, did not adversely affect the immune response engendered by Ty21a, as gauged by the combined IgG or IgA reseroconversion rates were virtually identical (88% vs. 87.5%) between the pooled groups. Concurrent immunization with oral sponse rate. However, the IgG response was somewhat lower in the group that received mefloquine (table 3) . polio vaccine or yellow fever vaccine did not impact the immune response evoked by CVD103-HgR given alone or in Discussion combination with Ty21a.
The MICs for mefloquine, chloroquine, and proguanil The current study demonstrated that the simultaneous administration of certain antimalarial drugs commonly given to travagainst Ty21a were 10 mg/mL, ú500 mg/mL, and ú200 mg/ Clearly, the concomitant administration of yellow fever or antibody response was used as a surrogate marker to predict a protective immune response. This approach is supported by oral polio vaccines did not affect the immune response to either the Ty21a or CVD103-HgR vaccine strain. The study design studies demonstrating that serum anti -S. typhi antibodies and vibriocidal antibodies correlate with protection against typhoid did not allow us to determine if there was any effect on the immunogenicity of the polio or yellow fever vaccines. There fever and cholera, respectively, in field trials and in volunteer challenge studies [2, 6, 15 -17] . Many antimalarial drugs, such has been some concern that immunization with live oral attenuated vaccines may elevate local gut interferon levels, which as chloroquine, mefloquine, and proguanil, have in vitro antibacterial activity that could limit in vivo replication of the could, in theory, diminish the potency of oral polio vaccine. However, without supporting data, the Centers for Disease vaccine strain, thereby diminishing efficacy. An important finding in the present investigation was that in vitro activity Control and Prevention found no reason to contraindicate the simultaneous use of oral polio vaccine and Ty21a [18]. of various antimalarial drugs was not predictive of their in vivo effect upon the immune response engendered by live oral
The above results illustrate that certain antimalarial drugs can exert a detrimental effect on the immunogenicity of the vaccines.
Despite the fact that mefloquine is highly active against the Ty21a and CVD103-HgR vaccine strains. Based on our current findings, a number of recommendations can be offered. ForeTy21a vaccine strain in vitro (MIC, 5 -10 mg/mL), it did not exert a significant negative effect on the combined serum antimost among these are that proguanil not be administered together with Ty21a and that chloroquine not be given simultane-S. typhi IgG or IgA antibody response. The fact that chloroquine also did not exert an immunosuppressive effect is not ously with CVD 103-HgR. Proguanil chemoprophylaxis should be initiated no sooner than 10 days after the last dose of Ty21a altogether surprising, given its high in vitro MIC (ú250 mg/ mL). However, the daily administration of proguanil did effect vaccine. This recommendation is based on the kinetics of the immune response after immunization with Ty21a, when neara marked reduction in the immune response engendered by Ty21a even though it had a MIC (ú200 mg/mL) comparable maximal serum antibody responses are observed Ç10 -14 days after completion of the vaccination regimen [9, 10]. The coadto that of chloroquine.
The effect of antimalarial drugs on the immune response ministration of mefloquine and Ty21a would most likely not compromise vaccine efficacy. Since protection against experiengendered by CVD103-HgR administered alone or in combination with Ty21a was more difficult to assess. While chlomental cholera is conferred as soon as 8 days after immunization with CVD103-HgR, chloroquine prophylaxis should be roquine resulted in a significant decline in both vibriocidal seroconversion rate and GMT when given with CVD103-HgR, initiated no sooner than 8 days after vaccination [18] . While mefloquine effected a decrease in the vibriocidal GMT, the this same effect was not seen when CVD103-HgR was combined with Ty21a. Similarly, mefloquine effected a decrease seroconversion rate was not significantly reduced. A minimal protective titer has yet to be determined for CVD103-HgR. As in the vibriocidal GMT only when administered with CVD103-HgR alone. However, the seroconversion rate in either group, noted above, the seroconversion rate was not adversely affected by ingestion of mefloquine. Therefore, the concomitant adminwhich appears to be the best predictor of immunity to experimentally induced cholera in volunteer studies [2, 16, 17] vaccines, especially when malaria prophylaxis is indicated.
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While the Ty21a vaccine formulation used in this study differs ment for the development of combined live oral vaccines
